Calton & Associates Inc. Buys Shares of 10,355 NeoGenomics, Inc. (NASDAQ:NEO) – Ticker Report
Other large investors have also made changes to their positions in the company. UBS Group AG grew its stake in shares of NeoGenomics by 107.6% in the third quarter. UBS Group AG now owns 82,782 shares of the medical research company’s stock worth $3,993,000 after acquiring an additional 42,913 shares during the period. Two Sigma Advisers LP bought a new stake in NeoGenomics in the 3rd quarter worth approximately $338,000. Lindbrook Capital LLC purchased a new stake in NeoGenomics during the 4th quarter valued at $84,000. National Bank of Canada FI bought a new position in shares of NeoGenomics during the 4th quarter valued at $126,000. Finally, New York State Teachers Retirement System lifted its holdings in shares of NeoGenomics by 1.0% during the 4th quarter. New York State Teachers Retirement System now owns 144,785 shares of the medical research company’s stock valued at $4,940,000 after buying an additional 1,400 shares during the period. 95.03% of the stock is currently owned by hedge funds and other institutional investors.
NEO opened at $8.94 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 7.64 and a current ratio of 7.93. NeoGenomics, Inc. has a fifty-two week low of $6.85 and a fifty-two week high of $54.74. The firm’s fifty day moving average is $8.47 and its 200 day moving average is $15.79. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -27.94 and a beta of 0.85.
NeoGenomics (NASDAQ:NEO – Get Rating) last posted its quarterly earnings results on Wednesday, April 27th. The medical research company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The business had revenue of $117.17 million for the quarter, compared to the consensus estimate of $116.44 million. NeoGenomics had a negative net margin of 7.33% and a negative return on equity of 6.62%. NeoGenomics’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.06) earnings per share. On average, equities research analysts predict that NeoGenomics, Inc. will post -1.03 earnings per share for the current year.
A number of research firms recently commented on NEO. SVB Leerink reduced their price objective on NeoGenomics from $45.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, March 29th. Cowen lowered their price objective on shares of NeoGenomics from $42.00 to $24.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 29th. Raymond James cut their target price on shares of NeoGenomics from $24.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, April 18th. Needham & Company LLC decreased their price target on shares of NeoGenomics from $29.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, March 29th. Finally, Bank of America cut shares of NeoGenomics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $25.00 to $18.00 in a research note on Tuesday, March 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, NeoGenomics has a consensus rating of “Moderate Buy” and an average target price of $20.82.
About NeoGenomics (Get Rating)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
Further Reading
- Get a free copy of the StockNews.com research report on NeoGenomics (NEO)
- Five Below Stock is a Recession Play
- Here’s How to Dollar Cost Average into Positions in a Bear Market
- MarketBeat: Week in Review 7/4 – 7/8
- AT&T (NYSE:T) Is Its Cheaper Valuation Worth A Buy?
- Levi Strauss Proves Resilient For Dividend Investors
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO – Get Rating).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source